ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: By specifically targeting the BCR-ABL fusion protein in CML and the KIT receptor tyrosine kinase in GIST, imatinib effectively inhibits the aberrant kinase activity, leading to the inhibition of cell proliferation and induction of apoptosis [128].